General information

Announcements(0)

Greetings from the Chair

Overview

Web abstract

Best Student Presentation Award

Selected programs of presentations in English

Registration

Registration (Non-presenters under 4th year underg

Information for Participants

Information for Presenters and Chairs

Banquet

Luncheon Seminar & Career Design Seminar

General information 2

Abstract Submission (Oral/Poster Presentation) for

Abstract Submission (Oral/Poster Presentation)

Timetable

Fri. Mar 29, 2024

Sat. Mar 30, 2024

Sun. Mar 31, 2024

Program

Sessions

Search presentations

20230323085903895_en.png

app_icon.png

Change account information such as the email address and password on the account setting screen common to Confit.

Login required to view

Password required to view

Presentation Information

Session Details

Enter the password to view the abstracts.<br><br>The password will be emailed to those who have completed the registration.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

Program Type

Profile management

Announcements

Bookmark

Download PDF for print

Pharmacokinetics of lipoprotein-associated drugs in hyperlipidemic patients

ADME, which determines human in vivo pharmacokinetics, can be subject to individual differences due to genetic and environmental factors. Moreover, when considering drug efficacy and side effects, variability can also arise due to factors such as the number of target molecules and their affinities. Considering the essence of drug development, it is considered essential to predict efficacy and side effects, taking individual differences into account, based not only on the understanding of ADME but also on information derived from biomarkers. This session, jointly organized with the Drug Interaction and Personalized Medicine Focus Group of the Academy of Pharmaceutical Science and Technology, Japan, aims to address how to approach individual differences caused by drug-metabolizing enzymes, transporters, plasma proteins, and even gut microbiota, based on the latest knowledge. Furthermore, discussions will focus on considering individual variabilities in clinical development, with a specific case regarding the dosage and administration setting of anti-PD-1 antibodies. We aim to deepen discussions with attendees on the common theme of "How pharmaceutical science and technology contribute to personalized medicine."

Pharmaceutical science and technology contributing to personalized medicine - from basic to clinical/development perspectives

The 144th Annual Meeting of the Pharmaceutical Society of Japan (Yokohama)

Presentation Information

[JS11-2]Pharmacokinetics of lipoprotein-associated drugs in hyperlipidemic patients

Password required to view